Race to replace injections for childhood dwarfism

Overview

For the estimated 250,000 people worldwide living with achondroplasia—the most common genetic cause of dwarfism—the only approved treatment required daily injections until BioMarin's Voxzogo. On February 12, 2026, BridgeBio reported that its oral pill achieved a 2.10 cm/year increase in height growth over placebo in a Phase 3 trial, exceeding Voxzogo's 1.57 cm/year gain and marking the first statistically significant improvement in body proportionality; two weeks later on February 27, the FDA approved Ascendis Pharma's once-weekly YUVIWEL (navepegritide) for children aged 2 and older.

With Voxzogo generating $735 million in 2024 sales and projected $900 million in 2025, the market now features daily, weekly injection, and pending oral options. BridgeBio plans regulatory filing in the second half of 2026, while YUVIWEL launches in early Q2 2026, intensifying competition and potentially expanding treatment adoption among families seeking less burdensome alternatives.

Play on this story Voices Debate Predict

Key Indicators

2.10 cm/yr

Height gain vs placebo

BridgeBio's infigratinib outperformed Voxzogo's 1.57 cm/year; YUVIWEL showed 1.49 cm/year in its trial

1 in 21,000

Birth prevalence

Approximately 250,000 people worldwide live with achondroplasia

$735M

Voxzogo 2024 sales

BioMarin's injectable grew rapidly since 2021 approval, ~$900M projected for 2025 amid new competition

Serious adverse events

No discontinuations or serious drug-related adverse events in BridgeBio's Phase 3 trial

Once-weekly

YUVIWEL dosing

FDA-approved injection for children 2+ years, first alternative to daily Voxzogo

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

People Involved

Neil Kumar, Ph.D.

Leading company through pivotal achondroplasia data readout

Organizations Involved

BridgeBio Pharma

Biopharmaceutical Company

Lead developer of oral achondroplasia treatment

BridgeBio develops therapies for genetic diseases through a network of subsidiary companies, with QED Therapeutics handling its FGFR inhibitor programs.

BioMarin Pharmaceutical

Biopharmaceutical Company

Market leader with only approved achondroplasia treatment

BioMarin developed Voxzogo (vosoritide), the first FDA-approved treatment for achondroplasia, now generating over $700 million in annual revenue.

Ascendis Pharma

Biopharmaceutical Company

FDA approval received for once-weekly YUVIWEL; launch planned early Q2 2026

Ascendis developed TransCon CNP (navepegritide), a once-weekly injection for achondroplasia awaiting FDA decision by February 28, 2026.

U.S. Food and Drug Administration

Federal regulatory agency

Approved three achondroplasia treatments: Voxzogo (daily), YUVIWEL (weekly), reviewing BridgeBio filing

The FDA approved the first achondroplasia treatment in 2021 and is now reviewing competitors while evaluating BridgeBio's planned submission.

Timeline

FDA Approves YUVIWEL, First Once-Weekly Achondroplasia Treatment
Regulatory

FDA grants accelerated approval to Ascendis Pharma's YUVIWEL (navepegritide) to increase linear growth in children 2 years and older with achondroplasia. Commercial availability expected early Q2 2026; Rare Pediatric Disease Priority Review Voucher also issued.
February 27th, 2026
BridgeBio Reports Positive Phase 3 Results
Clinical

BridgeBio announces PROPEL 3 Phase 3 trial met primary endpoint with 2.10 cm/year height gain versus placebo and achieved first statistically significant improvement in body proportionality for achondroplasia.
February 12th, 2026
FDA Delays Ascendis Decision
Regulatory

FDA extends review period for Ascendis's TransCon CNP by three months to February 28, 2026, citing a major amendment to the application.
November 25th, 2025
Phase 2 Results Published in NEJM
Publication

New England Journal of Medicine publishes BridgeBio's Phase 2 PROPEL 2 study results for infigratinib in achondroplasia.
November 18th, 2024
FDA Grants Breakthrough Therapy Designation
Regulatory

FDA designates BridgeBio's oral infigratinib as a Breakthrough Therapy for achondroplasia, potentially expediting review.
September 2024
BridgeBio Reports Durable Phase 2 Results
Clinical

BridgeBio announces 12- and 18-month data from PROPEL 2 Phase 2 trial showing sustained 2.5 cm/year height gains with infigratinib.
June 4th, 2024
BridgeBio Signs $100M Japan Deal
Business

BridgeBio's QED Therapeutics licenses infigratinib rights in Japan to Kyowa Kirin for $100 million upfront plus potential milestones.
February 2024
Voxzogo Expanded to All Ages
Regulatory

FDA approves supplemental application expanding Voxzogo to children of all ages with achondroplasia and open growth plates.
October 2023
FDA Approves First Achondroplasia Treatment
Regulatory

BioMarin's Voxzogo (vosoritide) receives accelerated FDA approval for children aged 5 and older with open growth plates, becoming the first drug approved to treat the genetic condition.
November 19th, 2021

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Predictions leaderboard

Infigratinib Approved, Reshapes Market

BridgeBio files for FDA approval in late 2026 and receives clearance in 2027. The oral formulation captures significant market share, particularly among families who struggled with daily injections. Voxzogo sales plateau while the achondroplasia market expands as more families choose treatment. BioMarin accelerates development of its long-acting weekly injection to compete on convenience.

Discussed by: Raymond James analysts, Fierce Biotech, BioPharma Dive

Consensus —

Three-Way Competition Emerges

Ascendis receives FDA approval for TransCon CNP in February 2026, creating a three-way market alongside Voxzogo and an eventually approved infigratinib. Physicians segment patients by preference: daily injection for those comfortable with current regimen, weekly injection for those wanting fewer shots, and oral for those seeking maximum convenience. Market expands significantly as treatment uptake increases.

Discussed by: BioSpace, industry analysts

Consensus —

Regulatory Delays Extend Voxzogo Dominance

FDA requests additional data from BridgeBio, delaying approval into 2028. Ascendis faces similar regulatory challenges. BioMarin maintains market leadership and advances BMN 333 into Phase 3, potentially offering a weekly alternative before oral competition arrives. The daily injection remains standard of care longer than expected.

Discussed by: Bernstein analysts, competitive dynamics observers

Consensus —

Long-Term Safety Concerns Emerge

Post-marketing surveillance or longer-term trial data reveals unexpected safety signals with one or more therapies targeting FGFR3 or CNP pathways. This could affect any competitor, potentially reshaping the market based on which approaches demonstrate the cleanest long-term profile. Physicians become more selective about which patients receive pharmacological treatment.

Discussed by: Medical literature, FDA safety reviews

Consensus —

Historical Context

Growth Hormone for Turner Syndrome (1997)

1997

What Happened

The FDA approved growth hormone treatment for Turner syndrome, a chromosomal condition causing short stature in girls. The approval established a precedent for pharmacological intervention in genetic growth disorders, though treatment required daily injections for years.

Outcome

Short Term

Treatment became standard of care for Turner syndrome, with most affected children receiving growth hormone therapy.

Long Term

Demonstrated that chronic injection therapy could be successfully adopted in pediatric populations, paving the way for Voxzogo's approach two decades later.

Why It's Relevant Today

Voxzogo's approval followed a similar regulatory path, and the Turner syndrome experience showed that families will accept daily injections for growth benefits—but also highlighted the opportunity for less burdensome alternatives.

Hepatitis C Oral Therapy Revolution (2013-2014)

December 2013 - October 2014

What Happened

Gilead's Sovaldi and Harvoni replaced interferon injections with oral pills for hepatitis C treatment. The shift from injectable regimens with severe side effects to well-tolerated oral pills transformed treatment uptake and cure rates.

Outcome

Short Term

Cure rates exceeded 95% as patients completed oral regimens they had previously abandoned due to injection burden.

Long Term

Hepatitis C became a curable disease for most patients. The example demonstrated how oral alternatives can dramatically expand treatment adoption.

Why It's Relevant Today

BridgeBio's oral infigratinib represents a similar shift from injection to pill. If approved, the convenience advantage could similarly expand treatment uptake among achondroplasia families who have declined or discontinued Voxzogo.

Limb Lengthening Surgery Era (1980s-Present)

1980s-present

What Happened

Before Voxzogo, the only intervention for achondroplasia height was limb lengthening surgery using distraction osteogenesis—a painful process involving cutting bones and gradually separating them over months. Patients underwent an average of 3-4 procedures to gain 10-15 cm of height.

Outcome

Short Term

Surgery provided meaningful height gains but with significant pain, complications, and years of recovery.

Long Term

Only about 19% of achondroplasia patients chose surgery, with nearly half uncertain whether to recommend it. The invasiveness created demand for pharmacological alternatives.

Why It's Relevant Today

Voxzogo's approval in 2021 marked the first non-surgical option. BridgeBio's oral therapy represents the next evolution—from surgery to injection to pill—potentially making treatment accessible to families who rejected both prior options.